150,931 Becton, Dickinson and Company $BDX Shares Acquired by Beutel Goodman & Co Ltd.

Beutel Goodman & Co Ltd. increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.0% during the third quarter, Holdings Channel reports. The institutional investor owned 1,835,571 shares of the medical instruments supplier’s stock after buying an additional 150,931 shares during the quarter. Becton, Dickinson and Company comprises about 2.6% of Beutel Goodman & Co Ltd.’s portfolio, making the stock its 6th largest holding. Beutel Goodman & Co Ltd.’s holdings in Becton, Dickinson and Company were worth $328,567,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the company. Brown Lisle Cummings Inc. lifted its stake in Becton, Dickinson and Company by 9.2% in the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier’s stock worth $97,000 after acquiring an additional 54 shares during the last quarter. Pension & Wealth Management Advisors Inc. grew its holdings in Becton, Dickinson and Company by 12.3% during the 3rd quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier’s stock worth $94,000 after acquiring an additional 56 shares in the last quarter. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 0.7% in the 3rd quarter. Brighton Jones LLC now owns 8,942 shares of the medical instruments supplier’s stock valued at $1,601,000 after purchasing an additional 58 shares during the last quarter. Elevation Point Wealth Partners LLC increased its position in shares of Becton, Dickinson and Company by 3.7% in the 2nd quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier’s stock valued at $256,000 after purchasing an additional 60 shares during the last quarter. Finally, Private Harbour Investment Management & Counsel LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% in the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier’s stock valued at $834,000 after purchasing an additional 62 shares in the last quarter. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BDX. JPMorgan Chase & Co. lifted their price objective on shares of Becton, Dickinson and Company from $170.00 to $202.00 and gave the stock a “neutral” rating in a research report on Friday. Piper Sandler raised their price target on Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday. Bank of America lifted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Citigroup lifted their price target on Becton, Dickinson and Company from $208.00 to $241.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wolfe Research assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, October 20th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $195.47.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at $20,380,155. This trade represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,462 shares of company stock valued at $1,456,770 in the last 90 days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Stock Up 1.5%

Shares of NYSE:BDX opened at $215.13 on Tuesday. The firm has a 50 day simple moving average of $188.68 and a 200-day simple moving average of $170.32. Becton, Dickinson and Company has a twelve month low of $138.31 and a twelve month high of $216.74. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $59.28 billion, a PE ratio of 51.96, a P/E/G ratio of 14.10 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, beating analysts’ consensus estimates of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $5.27 billion for the quarter, compared to the consensus estimate of $5.11 billion. During the same period last year, the firm posted $3.96 EPS. The company’s revenue was up 5.4% on a year-over-year basis. On average, equities analysts predict that Becton, Dickinson and Company will post 13.27 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be paid a $1.06 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. This represents a $4.24 annualized dividend and a yield of 2.0%. The ex-dividend date is Thursday, December 10th. Becton, Dickinson and Company’s payout ratio is currently 101.45%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Thursday, November 5th that permits the company to buy back 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to reacquire up to 3.6% of its shares through open market purchases. Share buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.